Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

Delayed Quote. Delayed  - 09/30 04:51:15 pm
12.38 USD   +0.65%
08/03 SUCAMPO PHARMAC : reports 2Q loss
08/03 Sucampo Reports Second Quarter 2016 Financial Results
07/29 Paul Edick Joins Sucampo’s Board of Directors
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
12.94(c) 12.97(c) 12.93(c) 12.3(c) 12.38 Last
257 929 287 924 244 121 258 716 83 470 Volume
-2.19% +0.23% -0.31% -4.87% +0.65% Change
More quotes
Financials ($)
Sales 2016 206 M
EBIT 2016 85,2 M
Net income 2016 14,4 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 229 M
EBIT 2017 109 M
Net income 2017 47,7 M
Debt 2017 89,8 M
Yield 2017 -
P/E ratio 2016 37,27
P/E ratio 2017 13,13
EV / Sales2016 3,42x
EV / Sales2017 2,85x
Capitalization 564 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
08/26 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/08 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/03 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/03 SUCAMPO PHARMACEUTICALS : reports 2Q loss
08/03 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
08/03 Sucampo Reports Second Quarter 2016 Financial Results
07/29 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
07/29 Paul Edick Joins Sucampo’s Board of Directors
07/20 Sucampo Announces Second Quarter 2016 Earnings Call
07/12 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
News from SeekingAlpha
09/02 BIOMERICA : The Next Major IBS Product
08/03 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2016 Results - Earn..
08/03 Sucampo revenues up 49%; Non-GAAP EPS up 10% in Q2
08/03 BIOTECH DAILY DIGEST : A Buyout For Biogen? The Rally Continues. Spotlight On Li..
08/03 Sucampo Pharmaceuticals, Inc. 2016 Q2 - Results - Earnings Call Slides
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 18,1 $
Spread / Average Target 47%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-28.86%564
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
More Results